Metformin Extended Release (XR)
Sponsors
Janssen Research & Development, LLC
Conditions
Healthy
Phase 1
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
CompletedNCT02846506
Start: 2016-08-31End: 2016-10-31Updated: 2025-02-03
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
CompletedNCT02851212
Start: 2016-08-31End: 2016-10-31Updated: 2016-12-02
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
CompletedNCT02851095
Start: 2016-08-31End: 2016-11-30Updated: 2025-02-03
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
CompletedNCT02865668
Start: 2016-08-31End: 2016-10-31Updated: 2025-02-03